파로스아이바이오
Financials
Valuation Metrics
파로스아이바이오's Market Cap is ₩713B. At end of 2025 it was ₩1216B. Ranked #1523 of 2,421 in KR market (top 63%), #894 of 1,640 on KOSDAQ (top 55%), #166 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 72%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 71.33B KRW | KR#1,523/2,421 Sec#166/231 |
| Net Income | -9.49B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 26.25B KRW | KR#2,357/2,421 Sec#225/231 |
| Net Assets | 9.72B KRW | KR#2,376/2,421 Sec#225/231 |
| Employees | 32 | KR#2,191/2,421 Sec#203/231 |
| Value | ||
| P/B | 7.34x | KR#2,316/2,421 Sec#203/231 |
| FCF Yield | -11.72% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -97.67% | KR#2,342/2,421 Sec#217/231 |
| ROA | -36.15% | KR#2,338/2,421 Sec#207/231 |
| Financial Health | ||
| Debt Ratio | 170.15% | KR#2,001/2,421 Sec#212/231 |
| Total Debt | 8.59B KRW | KR#1,674/2,421 Sec#152/231 |
| FCF | -8.36B KRW | KR#1,655/2,421 Sec#138/231 |
| Cash | 5.43B KRW | KR#1,972/2,421 Sec#180/231 |
| Current Ratio | 28.33x | KR#12/2,421 Sec#6/231 |
| Performance | ||
| 1Y Return | -7.71% | KR#911/2,421 Sec#55/231 |
| 1M Return | 2.61% | KR#972/2,421 Sec#71/231 |
| From 52W High | -54.54% | KR#1,625/2,421 Sec#122/231 |
| 1Y MDD | -62.91% | KR#1,640/2,421 Sec#133/231 |
| Trading | ||
| Volume | 31,683 shares | KR#1,356/2,421 Sec#131/231 |
| Trading Value | 174.5M KRW | KR#1,324/2,421 Sec#135/231 |
| Foreign Own. | 1.86% | KR#1,679/2,421 Sec#161/231 |
| Per Share | ||
| EPS | -733 KRW | KR—/2,421 Sec—/231 |
| BPS | 751 KRW | KR#2,352/2,421 Sec#219/231 |
Company Info
Pharos iBio, established in 2016 and listed on KOSDAQ in 2023 as a technology growth company, specializes in new drug development. The company operates an AI-based new drug development platform, Chemibus, integrating large-scale compound big data and multi-omics analysis technology. It focuses on innovative new drug development for rare and intractable diseases, particularly in oncology. Its flagship pipeline, PHI-101, has received orphan drug designation, aiming to accelerate development and enhance market competitiveness. Pharos iBio is headquartered in Anseong-si, Gyeonggi-do.